SequelSEC

Aquestive Therapeutics, Inc. AQST

Pharmaceutical Preparations · CIK 0001398733 · Fiscal year ends 1231

Revenue
$54.09M
Fiscal year ended 2026-06-30
Operating income
-$52.74M
Fiscal year ended 2026-06-30
Free cash flow
-$45.95M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$291.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.39Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue6.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-22.6%31th
R&D / revenue38.6%32th
Gross margin58.3%36th
CapEx / revenue1.3%42th
Current ratio3.14x43th
SBC / revenue17.1%45th
FCF margin-119.0%45th
Operating margin-159.5%53th
Net margin-188.1%48th

Aquestive Therapeutics, Inc. (AQST) reported revenue of $54.09M and net income of -$78.23M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Aquestive Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aquestive Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$54.09M
Cost of revenue$17.83M
Gross profit$36.26M
Operating income-$52.74M
Net income-$78.23M
Research & development$15.89M
Weighted-average diluted sharesUnavailable
Pretax income-$78.23M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$73.11M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Aquestive Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$98.49M
Total assets$132.10M
Current assets$118.49M
Total liabilities$188.69M
Current liabilities$16.48M
Total equity incl. NCI-$56.59M
Temporary (mezzanine) equityUnavailable
Inventory$7.37M
Accounts receivable$9.33M
GoodwillUnavailable
Long-term debt$50.65M
Accounts payable$8.96M

Cash flow

Aquestive Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$45.36M
Capital expenditures$584.00K
Investing cash flow-$584.00K
Financing cash flow$83.90M
Net change in cash$37.95M
Stock-based compensation$9.37M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$518.00K

Derived

Aquestive Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$45.95M
Gross margin67.0%
Operating margin-97.5%
FCF margin-85.0%
SBC / revenue17.3%
Current ratio7.19x
Revenue YoY growth22.6%
Net margin-144.6%
R&D / revenue29.4%
CapEx / revenue1.1%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AQST in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.